Ambitious academic AI institution opens in Paris

A European university with deep historic roots is now home to an AI research center whose areas of concentration include healthcare.

Sorbonne University announced the opening of the Sorbonne Center for Artificial Intelligence (SCAI) in Paris earlier this week.

The facility is set to host 100 scientists and 150 doctoral and post-doctoral researchers. And its initial headcount of around 300 students will include those attending a satellite center in the United Arab Emirates.

On Wednesday, the university, an offshoot of the Collège de Sorbonne founded in the 13th century, ran a quick Q&A with the inaugural director of SCAI (which is not to be confused with the U.S.-based organization using the same acronym, the Society for Cardiovascular Angiography and Interventions).

“Artificial intelligence raises more or less scientifically based concerns,” says the director, Gérard Biau, a Sorbonne professor of probability, statistics and modeling. “By mobilizing the critical spirit and the scientific approach, the human and social sciences will be able to help us to better analyze the relations that we have with these digital upheavals and their impacts on our existence.”

Along with healthcare, the new SCAI will concentrate on AI fundamentals and applications in mathematics, informatics, robotics, climate and environment, as well as on humanities issues that may be addressable by algorithms.  

Read the rest:

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.